Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

Miguel Otero, Sandra A. Calarota, Barbara Felber, Dominic Laddy, George Pavlakis, Jean D. Boyer, David B. Weiner

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

DNA vaccines have been effective at generating useful immune responses in many animal species. However, it is clearly desirable to increase their potency. The identification of adjuvants that increase their cell-mediated immune (CMI) response is therefore an important goal. Resiquimod is an imiquimod analog proven to activate dendritic cells through TLR-7. The adjuvant capacity of resiquimod has not, to our knowledge, been studied in the context of genetic immunization. Here, we studied resiquimod as an adjuvant for plasmid vaccine therapy by intra-muscular immunization of BALB/c mice with HIV-1 gag DNA vaccine without and with several concentrations of resiquimod (ranging from 5-100nM). We observed that resiquimod moderately enhanced IFN-γ production as measured by a peptide-based ELISPOT assay compared to that obtained in mice immunized with DNA gag only. Antigen-specific T-cell proliferation studies showed a several-fold increase in the stimulation index in mice immunized with DNA gag +50 nM of resiquimod as compared to mice receiving DNA gag alone. Antibody titer also increased, while the antibody isotyping data showed a strong Th1 biased type response. Analysis of cytokine production in serum samples demonstrated a stronger Th1 cytokine bias in the presence of resiquimod. Furthermore, relevant increase in IL-4 production, as measured by ELISPOT assay, was not observed. Our results show that resiquimod can have modest adjuvant activity, in a DNA formulation, driving the immune system towards a cell-mediated immune response. Additional studies involving this adjuvant for DNA vaccines are underway.

Original languageEnglish
Pages (from-to)1782-1790
Number of pages9
JournalVaccine
Volume22
Issue number13-14
DOIs
Publication statusPublished - Apr 16 2004

Fingerprint

resiquimod
Human immunodeficiency virus 1
adjuvants
HIV-1
Immunization
immunization
animal models
recombinant vaccines
DNA Vaccines
mice
DNA
cell-mediated immunity
Enzyme-Linked Immunospot Assay
cytokines
antibodies
imiquimod
assays
dendritic cells
interleukin-4
immune system

Keywords

  • HIV-1
  • Immunization
  • Resiquimod

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Otero, M., Calarota, S. A., Felber, B., Laddy, D., Pavlakis, G., Boyer, J. D., & Weiner, D. B. (2004). Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine, 22(13-14), 1782-1790. https://doi.org/10.1016/j.vaccine.2004.01.037

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. / Otero, Miguel; Calarota, Sandra A.; Felber, Barbara; Laddy, Dominic; Pavlakis, George; Boyer, Jean D.; Weiner, David B.

In: Vaccine, Vol. 22, No. 13-14, 16.04.2004, p. 1782-1790.

Research output: Contribution to journalArticle

Otero, M, Calarota, SA, Felber, B, Laddy, D, Pavlakis, G, Boyer, JD & Weiner, DB 2004, 'Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model', Vaccine, vol. 22, no. 13-14, pp. 1782-1790. https://doi.org/10.1016/j.vaccine.2004.01.037
Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine. 2004 Apr 16;22(13-14):1782-1790. https://doi.org/10.1016/j.vaccine.2004.01.037
Otero, Miguel ; Calarota, Sandra A. ; Felber, Barbara ; Laddy, Dominic ; Pavlakis, George ; Boyer, Jean D. ; Weiner, David B. / Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. In: Vaccine. 2004 ; Vol. 22, No. 13-14. pp. 1782-1790.
@article{1d0286e44a5b42bdb3bd3040e2a2a53c,
title = "Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model",
abstract = "DNA vaccines have been effective at generating useful immune responses in many animal species. However, it is clearly desirable to increase their potency. The identification of adjuvants that increase their cell-mediated immune (CMI) response is therefore an important goal. Resiquimod is an imiquimod analog proven to activate dendritic cells through TLR-7. The adjuvant capacity of resiquimod has not, to our knowledge, been studied in the context of genetic immunization. Here, we studied resiquimod as an adjuvant for plasmid vaccine therapy by intra-muscular immunization of BALB/c mice with HIV-1 gag DNA vaccine without and with several concentrations of resiquimod (ranging from 5-100nM). We observed that resiquimod moderately enhanced IFN-γ production as measured by a peptide-based ELISPOT assay compared to that obtained in mice immunized with DNA gag only. Antigen-specific T-cell proliferation studies showed a several-fold increase in the stimulation index in mice immunized with DNA gag +50 nM of resiquimod as compared to mice receiving DNA gag alone. Antibody titer also increased, while the antibody isotyping data showed a strong Th1 biased type response. Analysis of cytokine production in serum samples demonstrated a stronger Th1 cytokine bias in the presence of resiquimod. Furthermore, relevant increase in IL-4 production, as measured by ELISPOT assay, was not observed. Our results show that resiquimod can have modest adjuvant activity, in a DNA formulation, driving the immune system towards a cell-mediated immune response. Additional studies involving this adjuvant for DNA vaccines are underway.",
keywords = "HIV-1, Immunization, Resiquimod",
author = "Miguel Otero and Calarota, {Sandra A.} and Barbara Felber and Dominic Laddy and George Pavlakis and Boyer, {Jean D.} and Weiner, {David B.}",
year = "2004",
month = "4",
day = "16",
doi = "10.1016/j.vaccine.2004.01.037",
language = "English",
volume = "22",
pages = "1782--1790",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13-14",

}

TY - JOUR

T1 - Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

AU - Otero, Miguel

AU - Calarota, Sandra A.

AU - Felber, Barbara

AU - Laddy, Dominic

AU - Pavlakis, George

AU - Boyer, Jean D.

AU - Weiner, David B.

PY - 2004/4/16

Y1 - 2004/4/16

N2 - DNA vaccines have been effective at generating useful immune responses in many animal species. However, it is clearly desirable to increase their potency. The identification of adjuvants that increase their cell-mediated immune (CMI) response is therefore an important goal. Resiquimod is an imiquimod analog proven to activate dendritic cells through TLR-7. The adjuvant capacity of resiquimod has not, to our knowledge, been studied in the context of genetic immunization. Here, we studied resiquimod as an adjuvant for plasmid vaccine therapy by intra-muscular immunization of BALB/c mice with HIV-1 gag DNA vaccine without and with several concentrations of resiquimod (ranging from 5-100nM). We observed that resiquimod moderately enhanced IFN-γ production as measured by a peptide-based ELISPOT assay compared to that obtained in mice immunized with DNA gag only. Antigen-specific T-cell proliferation studies showed a several-fold increase in the stimulation index in mice immunized with DNA gag +50 nM of resiquimod as compared to mice receiving DNA gag alone. Antibody titer also increased, while the antibody isotyping data showed a strong Th1 biased type response. Analysis of cytokine production in serum samples demonstrated a stronger Th1 cytokine bias in the presence of resiquimod. Furthermore, relevant increase in IL-4 production, as measured by ELISPOT assay, was not observed. Our results show that resiquimod can have modest adjuvant activity, in a DNA formulation, driving the immune system towards a cell-mediated immune response. Additional studies involving this adjuvant for DNA vaccines are underway.

AB - DNA vaccines have been effective at generating useful immune responses in many animal species. However, it is clearly desirable to increase their potency. The identification of adjuvants that increase their cell-mediated immune (CMI) response is therefore an important goal. Resiquimod is an imiquimod analog proven to activate dendritic cells through TLR-7. The adjuvant capacity of resiquimod has not, to our knowledge, been studied in the context of genetic immunization. Here, we studied resiquimod as an adjuvant for plasmid vaccine therapy by intra-muscular immunization of BALB/c mice with HIV-1 gag DNA vaccine without and with several concentrations of resiquimod (ranging from 5-100nM). We observed that resiquimod moderately enhanced IFN-γ production as measured by a peptide-based ELISPOT assay compared to that obtained in mice immunized with DNA gag only. Antigen-specific T-cell proliferation studies showed a several-fold increase in the stimulation index in mice immunized with DNA gag +50 nM of resiquimod as compared to mice receiving DNA gag alone. Antibody titer also increased, while the antibody isotyping data showed a strong Th1 biased type response. Analysis of cytokine production in serum samples demonstrated a stronger Th1 cytokine bias in the presence of resiquimod. Furthermore, relevant increase in IL-4 production, as measured by ELISPOT assay, was not observed. Our results show that resiquimod can have modest adjuvant activity, in a DNA formulation, driving the immune system towards a cell-mediated immune response. Additional studies involving this adjuvant for DNA vaccines are underway.

KW - HIV-1

KW - Immunization

KW - Resiquimod

UR - http://www.scopus.com/inward/record.url?scp=1842578532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842578532&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2004.01.037

DO - 10.1016/j.vaccine.2004.01.037

M3 - Article

VL - 22

SP - 1782

EP - 1790

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13-14

ER -